Latest Protein-bound paclitaxel Stories
Cenomed BioSciences, LLC, a majority-owned subsidiary of Abraxis BioScience, Inc. (Nasdaq: ABII), and TorreyPines Therapeutics, Inc.
The National Comprehensive Cancer Network (NCCN), Abraxis BioScience (NASDAQ:ABII), and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform.
Biocon and Abraxis BioScience have launched Abraxane in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.
Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc.
Abraxis BioScience has received approval from the China State Food and Drug Administration to market Abraxane paclitaxel for injection for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. (NASDAQ:ABBI), an integra
LONDON (Reuters) - Anglo-Swedish drugmaker AstraZeneca Plc said on Thursday it had agreed to sell its U.S. anesthetics and analgesic product portfolio to Abraxis BioScience for $350 million.
- Having no light.